Evidence map›Paper›PMID 42058597›Full record

ArticleMolecular therapy. Oncology2026

Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma.

Dan Cappabianca, Mahmoud Toulany, Seth Zima, Amanda Shea, Jolanta Vidugiriene, Anthony Lauer, Kayla Sylvester, Varun Gnanasekar, Sean Foster, Rithvik Turaga and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dan CappabiancaDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
Mahmoud ToulanyDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
Seth ZimaCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Amanda SheaDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
Jolanta VidugirienePromega Corporation, Fitchburg, WI 53711, USA.
Anthony LauerPromega Corporation, Fitchburg, WI 53711, USA.
Kayla SylvesterPromega Corporation, Fitchburg, WI 53711, USA.
Varun GnanasekarDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
Sean FosterDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.
Rithvik TuragaCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Krishanu SahaCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Jose AyusoCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA.
Quaovi H SodjiDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI 53705, USA.

Funding

Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against NeuroblastomaK08CA285941 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Quaovi H Sodji · 2024 to 2026
$479k
NCI NIH HHS K08 CA285941
6 · The paper itself

Abstract

Manufacturing chimeric antigen receptor (CAR) T cells with a stem cell memory phenotype can enhance their persistence in patients. Histone deacetylase inhibitors (HDACis) targeting class I HDACs promote chromatin remodeling in virally manufactured CAR T cells, leading to the activation of the Wnt pathway, and ultimately improve CAR T cell persistence. However, it is unknown whether the persistence of CRISPR-engineered CAR T cells can also be enhanced through such HDACi-mediated epigenetic modulation. CAR T cells engineered using CRISPR-Cas9 to integrate a CAR construct into the T cell receptor alpha constant (

Indexed as

CAR T cellsCRISPRexhaustionHDAC inhibitormetabolismmitochondiaMT: Special Issue - Advancements in pediatric cancer therapyneuroblastomapre-clinicalstem cell memory

Identifiers

PMID42058597
PMCPMC13123348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.